Bicalutamide Alternatives Compared
| Bicalutamide | Pluvicto (lutetium lu 177 vipivotide tetraxetan) | Lupron Depot (leuprolide) |
|
|---|
| Bicalutamide | Pluvicto (lutetium lu 177 vipivotide tetraxetan) | Lupron Depot (leuprolide) |
|
|||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Prostate Cancer. Bicalutamide may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Prostate Cancer. Pluvicto may also be used for purposes not listed in this medication guide. |
Prescription only
Lupron Depot is a hormone deprivation treatment that may be used for the palliative care of advanced prostate cancer. The main side effects are hot flashes and general pain and it may cause... View more |
Related suggestions Prostate Cancer
Popular comparisons
|
|||||||||||||||||||||||
| More about Bicalutamide | More about Pluvicto (lutetium lu 177 vipivotide tetraxetan) | More about Lupron Depot (leuprolide) | ||||||||||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||||||||||
|
Bicalutamide has an average rating of 8.4 out of 10 from a total of 13 ratings on Drugs.com. 85% of reviewers reported a positive effect, while 8% reported a negative effect. |
Pluvicto has an average rating of 8.0 out of 10 from a total of 3 ratings on Drugs.com. 67% of reviewers reported a positive effect, while 0% reported a negative effect. |
Lupron Depot has an average rating of 5.8 out of 10 from a total of 237 ratings on Drugs.com. 43% of reviewers reported a positive effect, while 32% reported a negative effect. |
||||||||||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||||||||||
|
View all Bicalutamide side effects |
View all Pluvicto side effects |
View all Lupron Depot side effects |
||||||||||||||||||||||||
| Drug Class | ||||||||||||||||||||||||||
| Generic Availability | ||||||||||||||||||||||||||
|
Lower cost generic |
||||||||||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Bicalutamide prices |
View all Pluvicto prices |
View all Lupron Depot prices |
||||||||||||||||||||||||
| Dosage Forms | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
| Brand Names | ||||||||||||||||||||||||||
| Casodex |
N/A |
Other leuprolide brands include: Camcevi, Eligard, Fensolvi, Lupron, Lupron Depot-PED, Lutrate Depot | ||||||||||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||||||||||
|
240 hours |
41.6 hours |
4.25 hours |
||||||||||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
| Pregnancy Category | ||||||||||||||||||||||||||
|
Category X
Not for use in pregnancy
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
Category X
Not for use in pregnancy
See the full pregnancy warnings document. |
||||||||||||||||||||||||
| Drug Interactions | ||||||||||||||||||||||||||
|
A total of 383 drugs are known to interact with Bicalutamide:
|
A total of 220 drugs are known to interact with Pluvicto:
|
A total of 284 drugs are known to interact with Lupron Depot:
|
||||||||||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||
| Disease Interactions | ||||||||||||||||||||||||||
| First Approval Date | ||||||||||||||||||||||||||
|
October 04, 1995 |
March 23, 2022 |
January 26, 1989 |
||||||||||||||||||||||||
| WADA Class View classifications | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| More Information | ||||||||||||||||||||||||||
| Patient Resources | ||||||||||||||||||||||||||
| Professional Resources | ||||||||||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.